Indaptus Therapeutics, Inc. (INDP)

Market Cap	6.74M
Revenue (ttm)	n/a
Net Income (ttm)	-15.75M
Shares Out	572.66K
EPS (ttm)	-40.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	104,463
Open	11.30
Previous Close	11.11
Day's Range	11.30 - 12.33
52-Week Range	7.56 - 66.64
Beta	1.17
Analysts	Strong Buy
Price Target	8.50 (-27.78%)
Earnings Date	Aug 11, 2025

About INDP

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to I...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: INDP
• Website: https://indaptusrx.com

Analyst Summary

According to 2 analysts, the average rating for INDP stock is "Strong Buy." The 12-month stock price target is $8.5, which is a decrease of -27.78% from the latest price.

Price Target

$8.5

(-27.78% downside)

Analyst Consensus: Strong Buy